Genelux Corporation

NasdaqCM GNLX

Genelux Corporation Shareholders' Equity for the quarter ending September 30, 2024

Genelux Corporation Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: GNLX

Genelux Corporation

CEO	Mr. Thomas Zindrick J.D.
IPO Date	Jan. 26, 2023
Location	United States
Headquarters	2625 Townsgate Road
Employees	24
Sector	Healthcare
Industries Biotechnology Vaccines

Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key trends

Past 5 years